Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) announced that it is conducting a strategic review of its business to determine how to optimally deploy its capital to maximize shareholder return. On a preliminary unaudited basis, as of December 31, 2023, Aclaris? aggregate cash, cash equivalents and marketable securities was approximately $182 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.11 USD | -0.45% |
|
-1.77% | +5.71% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.71% | 79.46M | |
+21.85% | 46.93B | |
+37.63% | 39.08B | |
-8.05% | 38.48B | |
+29.04% | 31.01B | |
-13.75% | 26.14B | |
+10.65% | 25.88B | |
+38.43% | 12.53B | |
-6.92% | 11.36B | |
-12.29% | 10.65B |
- Stock Market
- Equities
- ACRS Stock
- News Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Conducts Strategic Review of Business